As part of its advocacy program in Europe, ACRO submits regulatory comments to European officials. This comment letter, submitted by ACRO to EMA in 2020 about EMA Draft Guidance on Points to Consider on implications of Coronavirus disease (COVID-19) on methodological aspects of ongoing clinical trials (EMA/158330/2020) Joint Industry Comment Letter from EFPIA, ACRO, EuropaBio, Vaccines Europe, EFSPI, and EUCROF can be found below.